Frequency of occurrence and daptomycin susceptibility rates of gram-positive organisms causing bloodstream infections in cancer patients

Journal of Chemotherapy

Volumn 20, Issue 5, 2008, Pages 570-576

  Sader, Helio S ^a,b   Fritsche, T R ^a   Jones, R N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteremia; Cancer; Daptomycin; Febrile neutropenic patient; Staphylococcus aureus

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CEFTRIAXONE; CLINDAMYCIN; COAGULASE; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN G; STREPTOMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BROTH DILUTION; CANCER PATIENT; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROCOCCUS; FREQUENCY ANALYSIS; GRAM POSITIVE BACTERIUM; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SOLID TUMOR; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 57049149220     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.5.570     Document Type: Article

References (21)

1. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005; 103 (6): 1103-13.
2. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003; 36 (9): 1103-10.
3. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of blood-stream infections on patient outcomes in the ICU setting. Chest. 2000; 118 (1): 146-55.
4. Zinner SH. New pathogens in neutropenic patients with cancer: An update for the new millennium. Int J Antimicrob Agents. 2000; 16 (2): 97-101.
5. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34 (6): 730-51.
6. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002; 34 (11): 1524-9.
7. Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control. 2006; 34 (8): 534-6.
8. Clinical and Laboratory Standards Institute. (CLSI). M100-S18, Performance standards for antimicrobial susceptibility testing, 18th informational supplement. Wayne, PA: CLSI. 2008.
9. Clinical and Laboratory Standards Institute. (CLSI). M7-A7, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition. Wayne, PA: CLSI.; 2006.
10. Ashour HM, el-Sharif A. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients. J Clin Oncol. 2007; 25 (36): 5763-9.
11. Gould IM. MRSA bacteraemia. Int J Antimicrob Agents. 2007; 30 Suppl 1: S66-70.
12. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr., Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42 (6): 2398-402.
13. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46 (2): 193-200.
14. Moellering RC. Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med. 2003; 138 (2): 135-42.
15. Fowler VG, Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006; 355 (7): 653-65.
16. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis. 2004; 38 (6): 864-70.
17. Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: A SENTRY Program Report (2003-2004). Int J Antimicrob Agents. 2007; 30 (2): 143-9.
18. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19,615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbioi Infect Dis. 2007; 57 (4): 459-65.
19. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother. 2006; 50 (7): 2330-6.
20. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003; 47 (5): 1714-8.
21. Package Insert. Cubicin (daptomycin for injection). Lexington MA. (Cubist Pharmaceuticals, Inc). Available at http://www.cubicin.com/ pdf/PrescribingInformation.pdf. Accessed on January 13, 2008.